RTP Mobile Logo

CME Information and Faculty Disclosures

OVERVIEW OF ACTIVITY

CME Information and Faculty Disclosures

OVERVIEW OF ACTIVITY

CME Information and Faculty Disclosures

OVERVIEW OF ACTIVITY

5MJCASH2016

OVERVIEW OF ACTIVITY

Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. These events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.

NeoadjuvantBC16/Patients

TARGET AUDIENCE
This activity is intended for medical oncologists and surgeons involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY

NeoadjuvantBC16

TARGET AUDIENCE
This activity is intended for medical oncologists and surgeons involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY

QualityCareTT115/Video

TARGET AUDIENCE
This activity is intended for medical oncologists.

MCRC115/Video

TARGET AUDIENCE
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of colorectal cancer (CRC).

MCRC115

OVERVIEW OF ACTIVITY

LCU215

OVERVIEW OF ACTIVITY

GrandRoundsProstate15

TARGET AUDIENCE
This activity is intended for urologists, medical and radiation oncologists and other healthcare providers involved in the treatment of prostate cancer.

OVERVIEW OF ACTIVITY
Prostate cancer is the most frequently diagnosed cancer in men, with more than 50% of all cases found in individuals aged 65 years or older. Among the 220,800 new diagnoses of prostate cancer estimated within the United States in 2015, more than 90% will be discovered in the local and regional stages of disease where 5-year survival estimates approach 100% with current therapeutic intervention. This statistic emphasizes the importance of early detection, the effectiveness of current treatments and the natural history of the disease.

BCUS115

OVERVIEW OF ACTIVITY

GOU115

OVERVIEW OF ACTIVITY

GOU115/Video

TARGET AUDIENCE
This activity is intended for gynecologic and medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

OVERVIEW OF ACTIVITY

HOU215

OVERVIEW OF ACTIVITY